Xinyi Township

Researchers are studying people in Asia and the United States who have chronic kidney disease CKD along with type 2 diabetes T2D to understand more about the use, safety, and effectiveness of the treatment finerenone in real-world settings. CKD is a long-term condition where the kidneys progressively lose function, and T2D is a condition where the body does not produce or use insulin properly, leading to high blood sugar that can damage the kidneys. Finerenone blocks certain proteins called mineralocorticoid receptors, which may help protect the kidneys, heart, and blood vessels. It was recently approved for use in the US, and this observational study aims to collect information on people receiving finerenone as part of their regular care. The study uses data from commercial electronic health records and national claims databases in Asia and the US, covering the period from July 1, 2021, to the most recent available data. Participants are adults with CKD and T2D who have started finerenone treatment prescribed by their doctors. Since this is an observational study, no new treatments or interventions are given by the researchers. Instead, the study collects existing data on participants, including their kidney function, heart health, other medical conditions, and medications used while on finerenone. Participants are not required to attend any study visits or tests specifically for this research. The researchers use already available health records to analyze participant characteristics, comorbidities, and medication use before and after starting finerenone. They also monitor outcomes such as kidney failure, cardiovascular events, and medication dosing over time. The study will continue until September 30, 2026, gathering long-term real-world information about finerenone use and safety in people with CKD and T2D.

This research aims to identify individuals who may be eligible for interventional studies related to Alzheimers Disease by assessing specific biomarkers and cognitive performance. It is a Phase 3 screening study sponsored by Hoffmann-La Roche designed to evaluate potential participants using blood tests and cognitive assessments. The study focuses on adults aged 50 to 90 years to find candidates for further Alzheimers disease research. Participants will not receive any treatment but will undergo blood draws to measure the concentration of the biomarker pTau217. They will also complete the International Shopping List Test ISLT to assess cognitive function. This screening process helps determine eligibility for linked interventional Alzheimers disease studies by combining biomarker and cognitive data. During the study, participants will provide blood samples and perform cognitive tests at the initial visit. Researchers will measure the pTau217 levels in blood and record cognitive scores from the ISLT. The study involves no experimental treatment, focusing solely on assessment. Participation lasts until the primary completion date, with data collected on Day 1 to evaluate potential eligibility for further trials.

Researchers are investigating how well the drug VITRAKVI generic name larotrectinib works and how well patients tolerate it in real-world use for those with TRK fusion cancer. This cancer type involves a genetic change called an NTRK gene fusion that can cause tumors to grow. The study includes adults and children with locally advanced or metastatic solid tumors that have this specific gene fusion, reflecting a variety of common and rare cancers. Patients enrolled in this observational study are those for whom their doctors have decided to treat with larotrectinib. Treatments and medical care follow local standard practices without interference from the study. Participants are grouped based on cancer types like gastrointestinal, head and neck, soft tissue sarcoma, CNS, lung, melanoma, pediatric tumors, and others. Data on treatments, other medications, disease changes, and health symptoms will be collected during routine care. Participants will be observed for 24 to 60 months. Researchers will collect information on treatment side effects up to 30 days after treatment ends and monitor responses, disease control, survival, doses, and developmental milestones for up to 8 years. Medical records, including height, weight, neurological assessments, and Tanner stage will be reviewed as part of this long-term observation.